Imlunestrant vs Tamoxifen (Soltamox)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2028 · NCT07905001 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Tamoxifen (Soltamox)
Marketed by Mayne Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04174352 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Imlunestrant | Tamoxifen (Soltamox) |
|---|---|---|
| PFS, median | 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT049753087 other results
| 20.2 vs 15.6vs Endocrine TherapyNCT006019002 other results
|
| OS, median | —Trial running · NCT04975308 | 47.2 vs 43.9vs Endocrine TherapyNCT006019001 other result
|
| ORR | 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
| 30%bNCT02668666 |
| Clinical benefit rate | 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
| 64%bNCT02668666 |
PFS, median
- Imlunestrant
- 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT04975308
7 other results
- 5.5 vs 3.8 NCT04975308
- 9.4 NCT04975308
- 5.5 NCT04975308
- 9.2 vs 7.4 NCT04975308
- 7.4 vs 5.5 NCT04975308
- 14.5 NCT04975308
- 9.2 NCT04975308
- Tamoxifen (Soltamox)
- 20.2 vs 15.6vs Endocrine TherapyNCT00601900
2 other results
- 5 NCT03045653
- 9.1 NCT02668666
OS, median
- Imlunestrant
- —Trial running · NCT04975308
- Tamoxifen (Soltamox)
- 47.2 vs 43.9vs Endocrine TherapyNCT00601900
1 other result
- 18.8 NCT02913430
ORR
- Imlunestrant
- 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 11.6% vs 5.9% NCT04975308
- 21.1% NCT04975308
- 9.4% NCT04975308
- Tamoxifen (Soltamox)
- 30%bNCT02668666
Clinical benefit rate
- Imlunestrant
- 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 46.4% vs 36.4% NCT04975308
- 62.9% NCT04975308
- 44.1% NCT04975308
- Tamoxifen (Soltamox)
- 64%bNCT02668666
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Imlunestrant: 7 of 7 rows · Tamoxifen (Soltamox): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Imlunestrant | Tamoxifen (Soltamox) Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 44.1% (n=213)a,b,c,d NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose62.9% (n=213) NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 64% (n=47)b,c,d NCT02668666 · Phase 2 · registry result, not featured evidence |
| ORR responder rate · % of participants No placebo or comparator arm | 9.4% (n=213)a,b,c,d NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose21.1% (n=213) NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 30% (n=47)b,c,d NCT02668666 · Phase 2 · registry result, not featured evidence |
| PFS time to event · months No placebo or comparator arm | 5.49 monthsa,b,c,d NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 3 more doses9.23 months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.36 months NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 14.52 months NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 9.13 monthsb,c,d NCT02668666 · Phase 2 · registry result, not featured evidence 2 other source trials5 months @ 156wkhigh dose NCT03045653 · Phase 2 · registry result, not featured evidence NA months NCT02913430 · Phase 1 · registry result, not featured evidence · combination |
| Dropout rate | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 0%e NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results0.1% NCT00036270 · Phase 3 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 99.2% NCT01124695 · Phase 2 · registry result, not featured evidence 10.7%TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 63.2% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 11.4% NCT02806544 · Phase 2 · registry result, not featured evidence 0% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT01027416 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | —e NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results— NCT00036270 · Phase 3 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence 8.9% NCT01124695 · Phase 2 · registry result, not featured evidence —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —high dose NCT03045653 · Phase 2 · registry result, not featured evidence 10.5% NCT00118157 · Phase 2 · registry result, not featured evidence · combination — NCT02806544 · Phase 2 · registry result, not featured evidence — NCT00365599 · Phase 2 · registry result, not featured evidence · combination — NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination — NCT02913430 · Phase 1 · registry result, not featured evidence · combination — NCT01027416 · Phase na · registry result, not featured evidence |
| Serious AEs | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 28.7%e NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results17.1% NCT00036270 · Phase 3 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 24.6% NCT01124695 · Phase 2 · registry result, not featured evidence —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 3.6%TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 100% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 0% NCT02806544 · Phase 2 · registry result, not featured evidence 9.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 0% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 0% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0% NCT01027416 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | e arthralgia 70.3% hypertension 59% proteinuria 47.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 11 more resultshot flush 31.3% arthralgia 23.8% fatigue 16.4% NCT00036270 · Phase 3 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence fatigue 14.8% back pain 13.9% nausea 11.5% NCT01124695 · Phase 2 · registry result, not featured evidence nausea 100% NCT02988986 · Phase 2 · registry result, not featured evidence · combination anemia 36.8% nausea 36.8% anorexia 31.6% NCT00118157 · Phase 2 · registry result, not featured evidence · combination fatigue - grade 2 18.6% nausea - grade 2 18.6% anorexia/weight loss - grade 2 16.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination hot flashes 58.3% pain 41.7% pain: breast 41.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination arthralgia 33.3% back pain 33.3% headache 33.3% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination blood and lymphatic system disorders - other 50% hypertension 50% neutrophil count decreased 50% NCT02913430 · Phase 1 · registry result, not featured evidence · combination headache 32.1% (placebo 0%) night sweats 32.1% (placebo 0%) irritability 28.6% (placebo 0%) NCT01027416 · Phase na · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Imlunestrant
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Tamoxifen (Soltamox)
show 1 more result
show 1 more result
show 1 more result
+ 3 further endpoints in the CSV export.
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2027 · NCT05514054 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Tamoxifen (Soltamox)
Marketed by Mayne Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04174352 (registry estimate)
Reported efficacy
Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) (mixed)
Result source: NCT00066690
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Imlunestrant: 8 of 8 rows · Tamoxifen (Soltamox): 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Imlunestrant | Tamoxifen (Soltamox) Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 44.1% (n=213)a,b,c,d NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose62.9% (n=213) NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 64% (n=47)b,c,d NCT02668666 · Phase 2 · registry result, not featured evidence |
| ORR responder rate · % of participants No placebo or comparator arm | 9.4% (n=213)a,b,c,d NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose21.1% (n=213) NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 30% (n=47)b,c,d NCT02668666 · Phase 2 · registry result, not featured evidence |
| PFS time to event · months | 5.55 vs 5.52 Investigator's Choice of Endocrine Therapy monthsa,e,f,d NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 3 more doses5.49 vs 3.84 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.23 vs 7.36 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7.43 vs 5.49 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 20.2 vs 15.6 Endocrine Therapy monthse,f,d NCT00601900 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 5.49 monthsa,b,c,d NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 3 more doses9.23 months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.36 months NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 14.52 months NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 9.13 monthsb,c,d NCT02668666 · Phase 2 · registry result, not featured evidence 1 other source trial5 months @ 156wkhigh dose NCT03045653 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 29.6%E+OFSg NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results26.7%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination 0% NCT00601900 · Phase 3 · registry result, not featured evidence · combination 10%TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence 9.1%TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination 0% NCT02668666 · Phase 2 · registry result, not featured evidence 99.2% NCT01124695 · Phase 2 · registry result, not featured evidence 3.2%Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence 20%Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination 10.7%TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 0% NCT01614210 · Phase 2 · registry result, not featured evidence 63.2% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 11.4% NCT02806544 · Phase 2 · registry result, not featured evidence 0% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 17.6% NCT00499083 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 13.2%E+OFSg NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results6.8%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination — NCT00601900 · Phase 3 · registry result, not featured evidence · combination —TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence —TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination — NCT02668666 · Phase 2 · registry result, not featured evidence 8.9% NCT01124695 · Phase 2 · registry result, not featured evidence —Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence —Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —high dose NCT03045653 · Phase 2 · registry result, not featured evidence — NCT01614210 · Phase 2 · registry result, not featured evidence 10.5% NCT00118157 · Phase 2 · registry result, not featured evidence · combination — NCT02806544 · Phase 2 · registry result, not featured evidence — NCT00365599 · Phase 2 · registry result, not featured evidence · combination — NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT00499083 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 37.5%E+OFSg NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results37.2%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination 28.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination 20.7%TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence 22.9%TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 24.6% NCT01124695 · Phase 2 · registry result, not featured evidence 0%Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence 0%Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 3.6%TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 1.9% NCT01614210 · Phase 2 · registry result, not featured evidence 100% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 0% NCT02806544 · Phase 2 · registry result, not featured evidence 9.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 0% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 33.3% NCT00499083 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | g hot flashes/flushes 81.9% pain - joint 77.7% fatigue (asthenia, lethargy, malaise) 59% NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 13 more resultshot flashes/flushes 80% pain - joint 69.5% sweating (diaphoresis) 61.7% NCT00066690 · Phase 3 · registry result, not featured evidence · combination arthralgia 70.3% hypertension 59% proteinuria 47.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination other/minor (not categorized) 24% bone pain 20.9% fatigue 15.6% NCT00295646 · Phase 3 · registry result, not featured evidence bone pain 29.3% other/minor (not categorized) 24.9% fatigue 18.2% NCT00295646 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence fatigue 14.8% back pain 13.9% nausea 11.5% NCT01124695 · Phase 2 · registry result, not featured evidence nausea 100% NCT02988986 · Phase 2 · registry result, not featured evidence · combination hot flashes 36.5% nausea 21.2% fatigue 9.6% NCT01614210 · Phase 2 · registry result, not featured evidence anemia 36.8% nausea 36.8% anorexia 31.6% NCT00118157 · Phase 2 · registry result, not featured evidence · combination fatigue - grade 2 18.6% nausea - grade 2 18.6% anorexia/weight loss - grade 2 16.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination hot flashes 58.3% pain 41.7% pain: breast 41.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination bone pain 33.3% hypokalemia 33.3% mucositis oral 33.3% NCT00499083 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dThe assessment timepoint is not available for both results.
- ePopulation context differs: eligible sex differs (FEMALE versus ALL).
- fTreatment context differs: combination versus monotherapy.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Imlunestrant
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Tamoxifen (Soltamox)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 3 more results
show 3 more results
show 2 more results
show 2 more results
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Imlunestrant's landscape · Tamoxifen (Soltamox)'s landscape